Advertisement
Singapore markets closed
  • Straits Times Index

    3,336.59
    +13.21 (+0.40%)
     
  • Nikkei

    38,487.90
    +433.77 (+1.14%)
     
  • Hang Seng

    18,079.61
    -150.58 (-0.83%)
     
  • FTSE 100

    8,275.38
    +44.33 (+0.54%)
     
  • Bitcoin USD

    67,663.66
    +608.21 (+0.91%)
     
  • CMC Crypto 200

    1,425.70
    -2.87 (-0.20%)
     
  • S&P 500

    5,277.51
    +42.03 (+0.80%)
     
  • Dow

    38,686.32
    +574.84 (+1.51%)
     
  • Nasdaq

    16,735.02
    -2.06 (-0.01%)
     
  • Gold

    2,347.70
    -18.80 (-0.79%)
     
  • Crude Oil

    77.18
    -0.73 (-0.94%)
     
  • 10-Yr Bond

    4.5140
    -0.0400 (-0.88%)
     
  • FTSE Bursa Malaysia

    1,596.68
    -7.58 (-0.47%)
     
  • Jakarta Composite Index

    6,970.74
    -63.41 (-0.90%)
     
  • PSE Index

    6,433.10
    +61.35 (+0.96%)
     

Pacific Biosciences of California First Quarter 2024 Earnings: Misses Expectations

Pacific Biosciences of California (NASDAQ:PACB) First Quarter 2024 Results

Key Financial Results

  • Revenue: US$38.8m (flat on 1Q 2023).

  • Net loss: US$78.2m (loss narrowed by 11% from 1Q 2023).

  • US$0.29 loss per share (improved from US$0.36 loss in 1Q 2023).

earnings-and-revenue-growth
earnings-and-revenue-growth

All figures shown in the chart above are for the trailing 12 month (TTM) period

Pacific Biosciences of California Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 7.6%. Earnings per share (EPS) also missed analyst estimates by 3.2%.

Looking ahead, revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Life Sciences industry in the US.

ADVERTISEMENT

Performance of the American Life Sciences industry.

The company's shares are down 3.3% from a week ago.

Risk Analysis

Before you take the next step you should know about the 4 warning signs for Pacific Biosciences of California (1 is a bit unpleasant!) that we have uncovered.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.